Skip to search formSkip to main contentSkip to account menu

stage IIIA non-small cell lung cancer

Known as: stage IIIA nonsmall cell lung cancer, lung cancer, non-oat cell, stage IIIA, NSCLC, stage IIIA 
Stage III non-small cell lung cancer is divided into stages IIIA and IIIB. In stage IIIA, cancer has spread to lymph nodes on the same side of the… 
National Institutes of Health

Related topics

Related topics

16 relations
ChestEGFR Gene MutationEGFR geneEpithelial Cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Myosin IIIa boosts elongation of stereocilia by transporting espin 1 to the plus ends of actin filaments
Two proteins implicated in inherited deafness, myosin IIIa, a plus-end-directed motor, and espin, an actin-bundling protein… 
Highly Cited
2007
Highly Cited
2007
Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial.
PURPOSE To investigate the role of prophylactic cranial irradiation (PCI) within a trimodality protocol (chemotherapy… 
Review
2007
Review
2007
The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with patients having a poor prognosis… 
Highly Cited
2003
Highly Cited
2003
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
PURPOSE A multicenter, phase II trial investigated the efficacy and toxicity of neoadjuvant docetaxel-cisplatin in locally… 
Highly Cited
2003
Highly Cited
2003
Association of Fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais.
We recently reported association of a newly identified polymorphism of Fcgamma receptor (FcgammaR) IIb, I232T, with systemic… 
Review
2001
Review
2001
Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.
BACKGROUND The number of N2 stations (single vs multiple N2 stations) is an important prognostic factor in patients with… 
Highly Cited
2001
Highly Cited
2001
Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma
A modified Phase I/II trial was conducted evaluating the incorporation of three‐dimensional conformal radiation therapy into a… 
Highly Cited
2000
Highly Cited
2000
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of…
PURPOSE Our objective was to better define the activity/feasibility of gemcitabine/cisplatin (GC) as induction chemotherapy in… 
Highly Cited
1997
Highly Cited
1997
Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
PURPOSE The main objectives of this study were (a) to ascertain the feasibility and toxicity of preoperative twice-daily… 
Highly Cited
1993
Highly Cited
1993
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)